WO2022004816A1 - 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤 - Google Patents

胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤 Download PDF

Info

Publication number
WO2022004816A1
WO2022004816A1 PCT/JP2021/024837 JP2021024837W WO2022004816A1 WO 2022004816 A1 WO2022004816 A1 WO 2022004816A1 JP 2021024837 W JP2021024837 W JP 2021024837W WO 2022004816 A1 WO2022004816 A1 WO 2022004816A1
Authority
WO
WIPO (PCT)
Prior art keywords
derived
cells
fetal
cranial nerve
culture supernatant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/024837
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
▲祐▼輔 相良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kochi University NUC
Original Assignee
Kochi University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kochi University NUC filed Critical Kochi University NUC
Priority to CN202180047221.2A priority Critical patent/CN115811981A/zh
Priority to US18/003,425 priority patent/US20230242870A1/en
Priority to JP2022534097A priority patent/JPWO2022004816A1/ja
Priority to EP21832276.6A priority patent/EP4173629A4/en
Publication of WO2022004816A1 publication Critical patent/WO2022004816A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)

Definitions

  • Perinatal cerebral disorders that cause cerebral palsy include hypoxic-ischemic encephalopathy, cerebral hemorrhage, and periventricular leukomalacia, and the main pathological conditions of these are intracellular Ca elevation and active oxygen resulting from mitochondrial dysfunction. It is an inflammatory condition called hypercytokine palsy associated with the increase in macrophage activation. In particular, cerebral hemorrhage is more likely to occur in premature infants, with the most severe symptoms and poor prognosis.
  • Non-Patent Document 1 Clinical studies have been conducted in which autologous bone marrow-derived mesenchymal cells are directly administered to patients with cerebral palsy, and their effectiveness has been reported.
  • Non-Patent Document 2 Although there are reports of administration of umbilical cord-derived cells, some motor functions have not been significantly improved (Non-Patent Document 2).
  • the cranial nerve regeneration promoter is a cranial nerve progenitor cell proliferation / survival promoter, a cranial nerve progenitor cell homing promoter, a cranial nerve progenitor cell differentiation / maturation promoter, or a combination thereof.
  • the cranial nerve regeneration promoting agent according to any one item.
  • the cranial nerve regeneration promoting agent according to any one of (13) to (16) which comprises a cytokine and a chemokine in the culture supernatant.
  • the cranial nerve regeneration promoting agent according to any one of (13) to (17) which comprises IL-6, CXCL1, CXCL7, CXCL8 and CCL2.
  • the "fetal appendage-derived tissue” (also referred to as “postpartum-derived tissue”) means a group of tissues excised during labor, such as the umbilical cord and fetal membrane (amniotic membrane, chorion, etc.). Includes umbilical cord), placenta, etc.
  • the fetal appendage-derived tissue of the present invention is not particularly limited as long as it is a fetal appendage-derived tissue collected from a mammal, and is, for example, a fetal appendage-derived tissue of a primate mammal. More preferably, it is a tissue derived from human fetal appendages.
  • the fetal appendage-derived tissue cell culture supernatant since the fetal appendage-derived tissue cell culture supernatant according to the present disclosure has a risk of infection by a contaminating virus or the like, it is preferable not to mix and culture the fetal appendage-derived tissue cells from the majority of donors. It should be noted that the culture supernatant of fetal appendage-derived tissue cells from a plurality of donors is advantageous in that it can be produced as a homogeneous therapeutic agent for cranial neuropathy.
  • the administration of the therapeutic agent for cranial nerve disorders is preferably parenteral administration, and the parenteral administration may be systemic administration or local administration.
  • parenteral administration may be systemic administration or local administration.
  • the method for administering the therapeutic agent for cranial neuropathy are not limited to the condition that the expected therapeutic effect is maintained, but for example, intravenous administration, intraarterial administration, intraportal administration, intradermal administration, and subcutaneous administration. Examples thereof include administration, intramuscular administration, intraperitoneal administration, transpulmonary administration (transpulmonary absorption), intraventricular administration, intrathecal administration, and nasal administration. Of these, nasal administration and the like are minimally invasive and are preferable.
  • a neural progenitor cells were seeded human neuroblastoma strains SH-SY5Y (ATCC, No. CRL-2226) in 96-well plastic plates at 2xl0 5 cells / mL in DMEM culture medium by 100 [mu] L. 100 ⁇ L of the various culture supernatants prepared in Example 1 were added, and the cells were cultured at 37 ° C. under 5% CO2 for 5 days. As a control, the same amount of the medium used for preparing various culture supernatants was added and cultured. After culturing, the images were taken with a phase-contrast microscope, and the length of the neurites was measured using the analysis software ImageJ (NIH).
  • Factors contained in the culture supernatant Factors contained in the culture supernatant of Walton collagen-derived mesenchymal cells, amniotic membrane-derived mesenchymal cells, and chorion-derived mesenchymal cells prepared in Example 1 are antibody arrays.
  • N 3 examined by (Human Cytokine Array C5, manufactured by RayBiotech).
  • cytokines such as IL-6
  • chemokines such as CCL2, CXCL1, CXCL5, CXCL7, CXCL8, GROa / b / g
  • growth factors such as BDNF and EGF
  • osteopontin are contained in the culture supernatant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PCT/JP2021/024837 2020-06-30 2021-06-30 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤 Ceased WO2022004816A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202180047221.2A CN115811981A (zh) 2020-06-30 2021-06-30 包含胎儿附属物来源组织细胞培养上清的脑神经损伤治疗剂
US18/003,425 US20230242870A1 (en) 2020-06-30 2021-06-30 Cranial nerve disorder therapeutic agent including culture supernatant of tissue cells derived from fetal appendage
JP2022534097A JPWO2022004816A1 (https=) 2020-06-30 2021-06-30
EP21832276.6A EP4173629A4 (en) 2020-06-30 2021-06-30 THERAPEUTIC AGENT FOR CRANIAL NERVE DISEASE USING CULTURE SUPERNATANT OF TISSUE CELLS FROM THE FETAL APPENDIX

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020113456 2020-06-30
JP2020-113456 2020-06-30
JP2020-149878 2020-09-07
JP2020149878A JP6967308B1 (ja) 2020-06-30 2020-09-07 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤

Publications (1)

Publication Number Publication Date
WO2022004816A1 true WO2022004816A1 (ja) 2022-01-06

Family

ID=78509585

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/024837 Ceased WO2022004816A1 (ja) 2020-06-30 2021-06-30 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤

Country Status (5)

Country Link
US (1) US20230242870A1 (https=)
EP (1) EP4173629A4 (https=)
JP (2) JP6967308B1 (https=)
CN (1) CN115811981A (https=)
WO (1) WO2022004816A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6967308B1 (ja) * 2020-06-30 2021-11-17 国立大学法人高知大学 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤
CN117679520A (zh) * 2022-09-09 2024-03-12 北京达尔文细胞生物科技有限公司 用于防治后遗症期面神经麻痹的药物组合物及其应用
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法
WO2025182103A1 (ja) * 2024-02-28 2025-09-04 セルソース株式会社 脳梗塞の機能予後改善用組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
US5415665A (en) 1991-03-19 1995-05-16 Utah Medical Products, Inc. Umbilical cord clamping, cutting, and blood collecting device and method
JP2007521793A (ja) 2003-06-27 2007-08-09 エチコン、インコーポレイテッド 分娩後由来細胞類を使用する、神経組織の再生および修復
WO2017204231A1 (ja) 2016-05-24 2017-11-30 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098361A2 (en) * 2001-06-01 2002-12-12 Xcyte Therapies, Inc. T cell induced tissue repair and regeneration
WO2006071778A2 (en) * 2004-12-23 2006-07-06 Ethicon Incorporated Treatment of parkinson's disease and related disorders using postpartum derived cells
EP2139497B1 (en) * 2007-04-13 2013-11-06 Stemnion, INC. Methods for treating nervous system injury and disease
JP6095893B2 (ja) * 2008-12-19 2017-03-15 デピュイ・シンセス・プロダクツ・インコーポレイテッド 傷害後の神経組織の再生および修復
SG174551A1 (en) * 2009-03-26 2011-10-28 Ethicon Inc Human umbilical cord tissue cells as therapy for alzheimer' s disease
MX2013006592A (es) * 2010-12-17 2014-02-06 Anthrogenesis Corp Tratamiento de lesion de la medula espinal y lesion traumatica de cerebro empleando celulas adherentes obtenidas del amnios.
US20120276215A1 (en) * 2011-04-26 2012-11-01 Riordan Neil H Therapeutic Conditioned Media
CN104321426A (zh) * 2012-03-28 2015-01-28 石匠株式会社 永生化干细胞以及以其生成物为有效成分的药物组合物和药物制剂
US10167448B2 (en) * 2013-12-12 2019-01-01 Samsung Life Public Welfare Foundation Pharmaceutical composition for treating cerebrovascular diseases, containing stem cell-derived exosome as active ingredient
DK3145493T3 (da) * 2014-05-18 2022-10-31 Childrens Medical Center Fremgangsmåder og sammensætninger vedrørende exosomer
EP3307286B1 (en) * 2015-06-12 2023-01-11 Hudson Institute of Medical Research Allogeneic mammalian amniotic exosomes for treating a fibrotic disease
KR20190109389A (ko) * 2016-11-03 2019-09-25 엑소스템 바이오텍 리미티드 간엽 줄기 세포 집단, 이들의 산물 및 이들의 용도
CA3064064A1 (en) * 2017-05-16 2018-11-22 Exostem Biotec Ltd. Methods of inhibiting aging and treating aging-related disorders
CA3069805A1 (en) * 2017-07-14 2019-01-17 Orbsen Therapeutics Limited Cd39 stromal stem cells methods of isolation and use
JP2020093988A (ja) * 2018-12-11 2020-06-18 株式会社 バイオミメティクスシンパシーズ 腸溶性カプセル
JP6967308B1 (ja) * 2020-06-30 2021-11-17 国立大学法人高知大学 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5415665A (en) 1991-03-19 1995-05-16 Utah Medical Products, Inc. Umbilical cord clamping, cutting, and blood collecting device and method
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
JP2007521793A (ja) 2003-06-27 2007-08-09 エチコン、インコーポレイテッド 分娩後由来細胞類を使用する、神経組織の再生および修復
WO2017204231A1 (ja) 2016-05-24 2017-11-30 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
AARTSMA-RUS ET AL., J. VIS. EXP, no. 85, 2014
BABA ET AL., PLOS ONE, vol. 14, no. 9, 2019, pages e0221111
BORUCZKOWSKI ET AL., INT. J. MOL. SCI, vol. 20, 2019, pages 2433
CUNNINGHAM CATRIONA J, REDONDO-CASTRO ELENA, ALLAN STUART M: "The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke", JOURNAL OF CEREBRAL BLOOD FLOW & METABOLISM, vol. 38, no. 8, 1 August 2018 (2018-08-01), US , pages 1276 - 1292, XP055897226, ISSN: 0271-678X, DOI: 10.1177/0271678X18776802 *
CYTOTHERAPY, vol. 15, no. 12, December 2013 (2013-12-01), pages 1549 - 62
CYTOTHERAPY, vol. 17, no. 2, 2015, pages 224 - 231
DURAI MURUGAN MUNISWAMI, L. VINOD KUMAR REDDY, KATARI VENKATESH, SANDHYA BABU , DWAIPAYAN SEN: "Neuropotency and Neurotherapeutic Potential of Human Umbilical Cord Stem Cell 's Secretome", REGENERATIVE ENGINEERING AND TRANSLATIONAL MEDICINE, vol. 5, no. 4, 19 March 2019 (2019-03-19), pages 420 - 434, XP009533978, ISSN: 2364-4141, DOI: 10.1007/s40883-019-00096-4 *
KOSSATZ ET AL., FRONT. PHARMACO, vol. 9, 2018, pages 376
MIEDEL ET AL., J. VIS. EXP, no. 123, 2017
NAZARINIA DONYA, ABOUTALEB NAHID, GHOLAMZADEH RAHELEH, NASSERI MALEKI SOLMAZ, MOKHTARI BEHNAZ, NIKOUGOFTAR MAHIN: "Conditioned medium obtained from human amniotic mesenchymal stem cells attenuates focal cerebral ischemia/reperfusion injury in rats by targeting mTOR pathway", JOURNAL OF CHEMICAL NEUROANATOMY, vol. 102, 1 December 2019 (2019-12-01), GB , pages 1 - 10, XP055897208, ISSN: 0891-0618, DOI: 10.1016/j.jchemneu.2019.101707 *
OH ET AL., EXP. MOL. MED, vol. 50, no. 4, 2018, pages 22
PISCHIUTTA, FRANCESCA; BRUNELLI, LAURA; ROMELE, PIETRO; SILINI, ANTONIETTA; SAMMALI, ELIANA; PARACCHINI, LARA; MARCHINI, SERGIO; T: "Protection of Brain Injury by Amniotic Mesenchymal Stromal Cell -Secreted Metabolites", CRITICAL CARE MEDICINE, vol. 44, no. 11, 2016, pages e1118 - e1131, XP009533995, DOI: 10.1097/CCM.0000000000001864 *
SARNYAI ET AL., PROC. NATL. ACAD. SCI. USA., vol. 97, no. 26, 2000, pages 14731
SAYAD MOHAMMAD TAGHI RAZAVI TOUSI , NASER AMIRIZADEH , FARINAZ NASIRINEZHAD , MAHIN NIKOUGOFTAR , MEYSAM GANJIBAKHSH , NAHID ABOUT: "A Rapid and Cost- Effective Protocol for Isolating Mesenchymal Stem Cells from the Human Amniotic Membrane", GALEN MEDICAL JOURNAL, vol. 6, no. 3, 2017, pages 217 - 225, XP055897214, DOI: 10.22086/gmj.v0i0.670 *
See also references of EP4173629A4
THOMI GIERIN, JOERGER-MESSERLI, HAESLER, MURI, SURBEK, SCHOEBERLEIN: "Intranasally Administered Exosomes from Umbilical Cord Stem Cells Have Preventive Neuroprotective Effects and Contribute to Functional Recovery after Perinatal Brain Injury", CELLS, vol. 8, no. 8, 8 August 2019 (2019-08-08), pages 1 - 20, XP055897217, DOI: 10.3390/cells8080855 *
WANG ET AL., ACTA MEDICA OKAYAMA, vol. 66, no. 6, 2012, pages 429
WANG ET AL., J MATERN FETAL NEONATAL MED, vol. 28, no. 7, 2015, pages 842 - 7
WANG ET AL., STEM CELL RESEARCH & THERAPY, vol. 8, 2017, pages 26
WATSON ET AL., NEUROSCIENCE LETTERS, vol. 715, 2020, pages 134533
YOON JONG HYUN, ROH EUN YOUN, SHIN SUE, JUNG NAM HEE, SONG EUN YOUNG, CHANG JU YOUNG, KIM BYOUNG JAE, JEON HYE WON: "Comparison of Explant-Derived and Enzymatic Digestion-Derived MSCs and the Growth Factors from Wharton’s Jelly", BIOMED RESEARCH INTERNATIONAL, vol. 2013, 9 April 2013 (2013-04-09), pages 1 - 8, XP055897222, ISSN: 2314-6133, DOI: 10.1155/2013/428726 *
ZHAO QIUCHEN; HU JINXIA; XIANG JIE; GU YUMING; JIN PEISHENG; HUA FANG; ZHANG ZUNSHENG; LIU YONGHAI; ZAN KUN; ZHANG ZUOHUI; ZU JIE;: "Intranasal administration of human umbilical cord mesenchymal stem cells-conditioned medium enhances vascular remodeling after stroke", BRAIN RESEARCH, vol. 1624, 13 August 2015 (2015-08-13), NL , pages 489 - 496, XP029290589, ISSN: 0006-8993, DOI: 10.1016/j.brainres.2015.08.003 *

Also Published As

Publication number Publication date
JP2022016722A (ja) 2022-01-24
US20230242870A1 (en) 2023-08-03
EP4173629A4 (en) 2024-08-21
CN115811981A (zh) 2023-03-17
EP4173629A1 (en) 2023-05-03
JPWO2022004816A1 (https=) 2022-01-06
JP6967308B1 (ja) 2021-11-17

Similar Documents

Publication Publication Date Title
JP6967308B1 (ja) 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤
Baez-Jurado et al. Secretome of mesenchymal stem cells and its potential protective effects on brain pathologies
Cunningham et al. The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke
US20200306318A1 (en) Adherent cells from placenta and use of same in disease treatment
Vawda et al. Mesenchymal cells in the treatment of spinal cord injury: current & future perspectives
US8475788B2 (en) Methods of treating spinal cord injury and minimizing scarring
US8263400B2 (en) Method for expanding adult stem cells from blood and compositions and methods for using the same
US9688733B2 (en) Method for treating spinal cord injury using HMGB1 fragment
KR102128224B1 (ko) 향상된 산후 부착형 세포 및 그의 제조 방법
JP7237301B2 (ja) 組織治癒剤
KR20260042390A (ko) Ptx-3, timp1 및 bdnf를 발현하는 간엽줄기세포를 유효성분으로 포함하는 염증 질환 또는 통증의 예방 또는 치료용 약학 조성물
CN120574767A (zh) 人胎盘源促血管干细胞hPASCs及其应用
CN112118851A (zh) 使用神经干细胞诱导血管生成的方法
WO2022004823A1 (ja) 臍帯血単核球細胞の培養上清を含む脳神経障害治療剤
CA3101965A1 (en) Tissue healing agent
Ma et al. SA/Col/SDF-1 neural scaffold promotes the homing of BMSCs and functional recovery in a rat model of traumatic brain injury
WO2018051340A1 (en) A process for retrieval of matrix dependent mesenchymal stromal cells from tissue
Siddiqui et al. Mechanisms Underpinning Beneficial
WO2022004822A1 (ja) 胎児付属物由来組織細胞及び／又は臍帯血細胞を培養するための海洋深層水を含む培地
Cohen Unresolved inflammation following spinal cord injury-causes and effects on the central nervous system
KR20200081685A (ko) 성체 줄기세포의 면역조절능을 증진시키기 위한 실크 피브로인 나노 파이버의 용도
HK1174356B (en) Adherent cells from placenta and use of same in disease treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21832276

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022534097

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021832276

Country of ref document: EP

Effective date: 20230130

WWW Wipo information: withdrawn in national office

Ref document number: 2021832276

Country of ref document: EP